FDA Misgivings About Reprints Would Not Make Them "False" - WLF Lawyer
This article was originally published in The Gray Sheet
Executive Summary
FDA would not be permitted to object to off-label reprints as "false and misleading" because the agency has technical problems with an article under the recent Washington Legal Foundation v. Henney ruling on off-label dissemination, Daniel Troy of the Washington D.C. law firm of Wiley, Rein & Fielding, asserted.
You may also be interested in...
WLF Decision Opens Door To Off-Label Promotion With Journal Reprints
Manufacturers can promote products for off-label uses with studies sponsored by competitors, according to the July 28 federal court decision against the FDA Modernization Act in Washington Legal Foundation v. Henney.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.